Investing.com - Financial Markets Worldwide
🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Supernus Pharmaceuticals Inc (SUPN)

NASDAQ
Currency in USD
36.85
+0.11(+0.30%)
Closed
Pre Market
37.39+0.54(+1.47%)
SUPN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Unlock Value
Day's Range
36.5937.28
52 wk Range
25.5339.37
Key Statistics
Edit
Prev. Close
36.85
Open
37.01
Day's Range
36.59-37.28
52 wk Range
25.53-39.37
Volume
253.58K
Average Volume (3m)
348.79K
1-Year Change
38.69%
Book Value / Share
18.28
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SUPN Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Technical Analysis
Strong Buy
Analysts Sentiment
Buy
Price Target
39.25
Upside
+6.51%
Members' Sentiments
Bearish
Bullish
ProTips
pro lock
Unlock All 16
Net income is expected to grow this year
Unlock InvestingPro

Supernus Pharmaceuticals Inc News & Analysis

Show more

Supernus Company Profile

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company’s commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company’s product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Industry
Pharmaceuticals
Sector
Healthcare
Employees
652
Market
United States

Compare SUPN to Peers and Sector

Metrics to compare
SUPN
Peers
Sector
Relationship
P/E Ratio
34.1x−11.9x−0.6x
PEG Ratio
0.26−0.120.00
Price/Book
2.0x3.9x2.6x
Price / LTM Sales
3.1x2.9x3.2x
Upside (Analyst Target)
6.2%134.0%40.6%
Fair Value Upside
Unlock17.9%7.1%Unlock

Analysts' Recommendations

2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 39.25

(+6.51% Upside)

More details

FAQ

What Is the Supernus (SUPN) Stock Price Today?

The Supernus stock price today is 36.85.

What Stock Exchange Does Supernus Trade On?

Supernus is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Supernus?

The stock symbol for Supernus is "SUPN."

What Is the Supernus Market Cap?

As of today, Supernus market cap is 2.04B.

What is Supernus Earnings Per Share?

The Supernus EPS is 1.09.

What Is the Next Supernus Earnings Date?

Supernus will release its next earnings report on 03 Mar 2025.

From a Technical Analysis Perspective, Is SUPN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.